NASH	Nonalcoholic steatohepatitis
NAFLD	Nonalcoholic fatty liver disease
MAFLD	Metabolic dysfunction-associated fatty liver disease
MASLD	Metabolic dysfunction-associated steatotic liver disease
MASH	Metabolic dysfunction-associated steatohepatitis
CAP	Controlled Attenuation Parameter
MRI-PDFF	Magnetic resonance imaging–proton density fat fraction
T2DM	Type 2 diabetes mellitus
FLI	Fatty liver index
MetALD	Metabolic dysfunction-associated steatotic liver disease and Alcohol-related liver disease
EASL–EASD–EASO	European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity
GLP-1RAs	Glucagon-like peptide-1 receptor agonists
SGLT-2i	Sodium–Glucose Co-transporter Inhibitors
ROS	Reactive oxygen species
LPS	Lipopolysaccharide
TLR	Toll-like receptors
HCC	hepatocellular carcinoma
MACE	major adverse cardiovascular events
ADA/EASD	American Diabetes Association/European Association for the Study of Diabetes
FIB-4	Fibrosis-4
NFS	Nonalcoholic Fatty Liver Disease Fibrosis Score
VCTE	vibration-controlled transient elastography
MRE	magnetic resonance elastography
APRI	AST-to-platelet ratio index
LSM	Liver stiffness measurement
LSV	Liver stiffness value
HbA1c	Hemoglobin A1c
MRI	Magnetic resonance imaging
DPP-4	Dipeptidyl peptidase-4
SGLT2	Sodium glucose co-transporter-2
GLP-1	Glucagon-like peptide-1